

Cathy Eng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8298880/publications.pdf>

Version: 2024-02-01

243
papers

17,317
citations

19608

61
h-index

15218

126
g-index

266
all docs

266
docs citations

266
times ranked

18653
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases. <i>Journal of Clinical Oncology</i> , 2006, 24, 2065-2072.	0.8	1,198
2	Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 3677-3683.	0.8	1,166
3	Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases. <i>Annals of Surgery</i> , 2005, 241, 715-724.	2.1	966
4	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2311-2319.	0.8	884
5	Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point After Resection of Hepatic Colorectal Metastases. <i>Journal of Clinical Oncology</i> , 2008, 26, 5344-5351.	0.8	548
6	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020, 25, e936-e945.	1.9	520
7	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	0.8	454
8	Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. <i>Journal of Clinical Oncology</i> , 2010, 28, 453-459.	0.8	440
9	Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1770-1776.	0.8	427
10	American Society of Clinical Oncology 2009 Clinical Evidence Review on Radiofrequency Ablation of Hepatic Metastases From Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 493-508.	0.8	399
11	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 849-861.	5.1	368
12	High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome. <i>Journal of Clinical Oncology</i> , 2011, 29, 1083-1090.	0.8	367
13	Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. <i>Cancer</i> , 2007, 110, 2761-2767.	2.0	347
14	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2017, 18, 446-453.	5.1	322
15	Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. <i>Cancer</i> , 2007, 109, 1750-1755.	2.0	294
16	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018, 24, 1062-1072.	3.2	225
17	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770.	12.5	218
18	Phase II Study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2009, 27, 2598-2603.	0.8	208

#	ARTICLE	IF	CITATIONS
19	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 2782-2797.	0.8	201
20	A Novel Platform for Detection of CK+ and CK ⁻ CTCs. <i>Cancer Discovery</i> , 2011, 1, 580-586.	7.7	189
21	Oxaliplatin-Mediated Increase in Spleen Size As a Biomarker for the Development of Hepatic Sinusoidal Injury. <i>Journal of Clinical Oncology</i> , 2010, 28, 2549-2555.	0.8	188
22	Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1976 to 2005. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 573-580.	0.6	187
23	Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 60, 1098-1105.	0.4	184
24	Overtreatment of Young Adults With Colon Cancer. <i>JAMA Surgery</i> , 2015, 150, 402.	2.2	180
25	Phase II Trial of Neoadjuvant Bevacizumab, Capecitabine, and Radiotherapy for Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 824-830.	0.4	177
26	Predictors and Patterns of Recurrence After Definitive Chemoradiation for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 794-800.	0.4	176
27	Clinical and Pathologic Predictors of Locoregional Recurrence, Distant Metastasis, and Overall Survival in Patients Treated With Chemoradiation and Mesorectal Excision for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 219-224.	0.6	158
28	Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. <i>Journal of Gastrointestinal Surgery</i> , 2007, 11, 1498-1505.	0.9	149
29	SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. <i>Investigational New Drugs</i> , 2012, 30, 1646-1651.	1.2	135
30	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018, 24, 181-188.	3.2	127
31	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2019, 269, 917-923.	2.1	121
32	Association of Age With Survival in Patients With Metastatic Colorectal Cancer: Analysis From the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2014, 32, 2975-2982.	0.8	118
33	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 5852-5858.	3.2	116
34	Hyperfractionated Accelerated Radiotherapy for Rectal Cancer in Patients With Prior Pelvic Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 60-65.	0.4	115
35	Phase II study of capecitabine (Xeloda [®]) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 762-771.	0.4	110
36	Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin. <i>Cancer</i> , 2010, 116, 316-322.	2.0	109

#	ARTICLE	IF	CITATIONS
37	Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2014, 13, 164-171.	1.0	108
38	Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015, 51, 271-281.	1.3	108
39	Long-term quality of life after radiotherapy for the treatment of anal cancer. <i>Cancer</i> , 2010, 116, 822-829.	2.0	106
40	The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2013, 8, e77117.	1.1	106
41	Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 4240-4250.	3.2	102
42	The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. <i>Oncotarget</i> , 2014, 5, 11133-11142.	0.8	102
43	Long-Term Survival and Recurrence Outcomes Following Surgery for Distal Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2010, 17, 2863-2869.	0.7	100
44	Practical Application of a Calculator for Conditional Survival in Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5938-5943.	0.8	95
45	Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. <i>Oncotarget</i> , 2016, 7, 76250-76260.	0.8	93
46	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. <i>Journal of Clinical Oncology</i> , 2020, 38, 2510-2518.	0.8	92
47	Improving the AJCC/TNM Staging for Adenocarcinomas of the Appendix. <i>Annals of Surgery</i> , 2013, 257, 1072-1078.	2.1	91
48	Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 623-633.	1.5	90
49	Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. <i>Supportive Care in Cancer</i> , 2014, 22, 1223-1231.	1.0	86
50	Metformin use and improved response to therapy in rectal cancer. <i>Cancer Medicine</i> , 2013, 2, 99-107.	1.3	85
51	American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2016, 34, 1803-1812.	0.8	83
52	Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). <i>Cancer</i> , 2010, 116, 2053-2063.	2.0	79
53	Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. <i>Cancer</i> , 2010, 116, 5325-5335.	2.0	77
54	The current landscape of locally advanced rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 649-659.	12.5	76

#	ARTICLE	IF	CITATIONS
55	Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2014, 109, 740-745.	0.8	75
56	Patterns of Locoregional Recurrence After Surgery and Radiotherapy or Chemoradiation for Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 71, 1175-1180.	0.4	74
57	<i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279.	0.8	69
58	Genetic Polymorphisms in MicroRNA-Related Genes as Predictors of Clinical Outcomes in Colorectal Adenocarcinoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 3982-3991.	3.2	67
59	Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. <i>Cancer</i> , 2009, 115, 5432-5440.	2.0	65
60	Intensity-modulated Radiation Therapy With Concurrent Chemotherapy for Anal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 461-466.	0.6	65
61	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0173345.	1.1	65
62	Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C. <i>Annals of Surgical Oncology</i> , 2009, 16, 2181-2187.	0.7	64
63	Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UIMP): Prognostic Factors and Implications for Treatment and Follow-up. <i>Annals of Surgical Oncology</i> , 2017, 24, 187-193.	0.7	62
64	Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2631-2638.	0.8	62
65	Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 207-218.	12.5	61
66	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3263-3272.	3.2	61
67	Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Molecular Cancer Research</i> , 2017, 15, 1542-1550.	1.5	59
68	Metastasis regulation by PPAR δ expression in cancer cells. <i>JCI Insight</i> , 2017, 2, e91419.	2.3	58
69	A Quantitative Sensory Analysis of Peripheral Neuropathy in Colorectal Cancer and Its Exacerbation by Oxaliplatin Chemotherapy. <i>Cancer Research</i> , 2014, 74, 5955-5962.	0.4	57
70	A Twenty-Year Experience with Adenocarcinoma of the Anal Canal. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1375-1380.	0.7	56
71	Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 818-823.	0.4	55
72	Subclinical Peripheral Neuropathy Is a Common Finding in Colorectal Cancer Patients Prior to Chemotherapy. <i>Clinical Cancer Research</i> , 2012, 18, 3180-3187.	3.2	55

#	ARTICLE	IF	CITATIONS
73	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a <i>de novo</i> phenomenon. <i>Oncotarget</i> , 2016, 7, 54627-54631.	0.8	53
74	Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. <i>Cancer</i> , 2013, 119, 4231-4241.	2.0	52
75	A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. <i>International Journal of Cancer</i> , 2016, 139, 177-186.	2.3	52
76	Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. <i>Cancer</i> , 2011, 117, 3713-3722.	2.0	51
77	Global and targeted serum metabolic profiling of colorectal cancer progression. <i>Cancer</i> , 2017, 123, 4066-4074.	2.0	51
78	Molecular Biomarkers Correlate with Disease-Free Survival in Patients with Anal Canal Carcinoma Treated with Chemoradiation. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1098-1105.	1.1	50
79	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4146-4154.	3.2	50
80	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1924-1931.	3.2	50
81	A comprehensive framework for early-onset colorectal cancer research. <i>Lancet Oncology</i> , The, 2022, 23, e116-e128.	5.1	49
82	Cetuximab in the treatment of patients with colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 937-949.	1.4	48
83	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. <i>Carcinogenesis</i> , 2012, 33, 1327-1331.	1.3	46
84	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2017, 122, 146-151.	0.3	45
85	Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results Medicare data, 1998-2007. <i>Cancer</i> , 2014, 120, 1162-1170.	2.0	43
86	Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. <i>Cancer</i> , 2017, 123, 1989-1997.	2.0	43
87	Anal Cancer: Current and Future Methodology. <i>Cancer Investigation</i> , 2006, 24, 535-544.	0.6	42
88	The Evolving Role of Monoclonal Antibodies in Colorectal Cancer: Early Presumptions and Impact on Clinical Trial Development. <i>Oncologist</i> , 2010, 15, 73-84.	1.9	42
89	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. <i>Oncotarget</i> , 2016, 7, 67495-67506.	0.8	42
90	Impact of Molecular Alterations and Targeted Therapy in Appendiceal Adenocarcinomas. <i>Oncologist</i> , 2013, 18, 1270-1277.	1.9	41

#	ARTICLE	IF	CITATIONS
91	The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. <i>Oncologist</i> , 2016, 21, 563-570.	1.9	40
92	The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 1276-1285.	0.6	33
93	Association of <i>CHFR</i> Promoter Methylation with Disease Recurrence in Locally Advanced Colon Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4531-4540.	3.2	32
94	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017, 24, 4051-4058.	0.7	32
95	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019, 121, 505-510.	2.9	32
96	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. <i>Annals of Surgical Oncology</i> , 2017, 24, 2646-2654.	0.7	30
97	Intensity-Modulated Radiation Therapy for the Treatment of Squamous Cell Anal Cancer With Para-aortic Nodal Involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 75, 791-794.	0.4	29
98	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018, 100, 35-45.	1.3	29
99	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
100	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2015, 20, 1247-1252.	1.9	28
101	Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. <i>Cancer</i> , 2013, 119, 3769-3775.	2.0	27
102	Bevacizumab in the Treatment of a Patient with Metastatic Colorectal Carcinoma with Brain Metastases. <i>Clinical Colorectal Cancer</i> , 2008, 7, 65-68.	1.0	26
103	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. <i>Cancer</i> , 2010, 116, 4086-4094.	2.0	26
104	The promise of mTOR inhibitors in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1775-1788.	1.9	26
105	Epidermal growth factor receptor inhibition in metastatic anal cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 804-808.	0.7	26
106	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017, 2, .	2.3	26
107	Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. <i>Oncology</i> , 2016, 90, 127-135.	0.9	25
108	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017, 12, e0183949.	1.1	25

#	ARTICLE	IF	CITATIONS
109	Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 163-166.	0.6	24
110	Survival Benefit Associated With Surgical Oophorectomy in Patients With Colorectal Cancer Metastatic to the Ovary. <i>Clinical Colorectal Cancer</i> , 2012, 11, 191-194.	1.0	22
111	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020, 46, 955-966.	0.5	22
112	Preoperative Radiation Therapy With Concurrent Capecitabine, Bevacizumab, and Erlotinib for Rectal Cancer: A Phase 1 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 301-305.	0.4	21
113	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 277-282.	0.6	20
114	Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 990-997.	0.6	19
115	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , 2018, 67, 1095-1102.	6.1	19
116	Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 102-108.	0.4	19
117	Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 283.	1.7	19
118	Treatment Options in Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Current Treatment Options in Oncology</i> , 2008, 9, 400-407.	1.3	18
119	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. <i>Advances in Radiation Oncology</i> , 2017, 2, 455-464.	0.6	18
120	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 959-967.	0.8	18
121	The Management and Prevention of Anal Squamous Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 216-225.	1.8	18
122	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. <i>British Journal of Cancer</i> , 2020, 123, 1262-1270.	2.9	18
123	Neoadjuvant Chemotherapy for Colon Cancer. <i>Cancers</i> , 2020, 12, 2368.	1.7	18
124	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. <i>Oncotarget</i> , 2020, 11, 1334-1343.	0.8	18
125	Chemotherapy and radiation of anal canal cancer: the first approach. <i>Surgical Oncology Clinics of North America</i> , 2004, 13, 309-320.	0.6	17
126	Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 662-671.	0.6	17

#	ARTICLE	IF	CITATIONS
127	Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. <i>Journal of Clinical Oncology</i> , 2008, 26, 2000-2005.	0.8	16
128	Fatal Diffuse Alveolar Damage Associated with Oxaliplatin Administration. <i>Clinical Colorectal Cancer</i> , 2011, 10, 198-202.	1.0	16
129	The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. <i>British Journal of Cancer</i> , 2021, 124, 797-804.	2.9	16
130	Prognostic factors for squamous cell cancer of the anal canal. <i>Gastrointestinal Cancer Research: GCR</i> , 2008, 2, 10-4.	0.8	16
131	A contemporary systematic review on liver transplantation for unresectable liver metastases of colorectal cancer. <i>Cancer</i> , 2022, 128, 2243-2257.	2.0	16
132	Measurement of DNA damage in peripheral blood by the γ -H2AX assay as predictor of colorectal cancer risk. <i>DNA Repair</i> , 2017, 53, 24-30.	1.3	15
133	Are Herbal Medicines Ripe for the Cancer Clinic?. <i>Science Translational Medicine</i> , 2010, 2, 45ps41.	5.8	14
134	Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. <i>Cancer</i> , 2012, 118, 6188-6198.	2.0	14
135	Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 632-637.	0.6	14
136	Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. <i>BMJ Supportive and Palliative Care</i> , 2021, 11, 170-179.	0.8	14
137	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , 2021, 17, 3151-3162.	1.1	14
138	Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. <i>Oncotarget</i> , 2014, 5, 6584-6593.	0.8	14
139	Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case-only analysis. <i>Molecular Carcinogenesis</i> , 2010, 49, 974-980.	1.3	13
140	Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , 2017, 123, 3367-3376.	2.0	13
141	First-in-Human PET Imaging and Estimated Radiation Dosimetry of I-[¹¹ C]-Glutamine in Patients with Metastatic Colorectal Cancer. <i>Journal of Nuclear Medicine</i> , 2022, 63, 36-43.	2.8	13
142	Anal Cancer: Emerging Standards in a Rare Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 2774-2788.	0.8	13
143	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	12
144	Current treatment and future directions in the management of anal cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 183-195.	157.7	12

#	ARTICLE	IF	CITATIONS
145	Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. <i>BMC Cancer</i> , 2017, 17, 331.	1.1	11
146	Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery. <i>Current Oncology Reports</i> , 2018, 20, 3.	1.8	11
147	Emerging drugs for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 629-642.	1.0	10
148	Multidetector Computed Tomography Follow-up of Hypoattenuating Small Liver Lesions in Patients With Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 411-416.	0.6	10
149	Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery. <i>Annals of Surgical Oncology</i> , 2017, 24, 1376-1377.	0.7	10
150	Physician interpretation of genomic test results and treatment selection. <i>Cancer</i> , 2018, 124, 966-972.	2.0	10
151	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 903-908.	2.3	10
152	Minimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis. <i>Hpb</i> , 2018, 20, 1150-1156.	0.1	10
153	Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. <i>Gastroenterology</i> , 2020, 159, 1605-1608.	0.6	10
154	Extended <i>RAS</i> Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021, 26, e261-e269.	1.9	10
155	Age-standardised incidence rate and epidemiology of colorectal cancer in Africa: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e052376.	0.8	10
156	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022, 5, e2213588.	2.8	10
157	Atypical Metastatic Presentations in Colorectal Cancer: A Case Series. <i>Clinical Colorectal Cancer</i> , 2014, 13, e1-e4.	1.0	9
158	Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study. <i>Indian Journal of Surgical Oncology</i> , 2015, 6, 198-206.	0.3	9
159	POLE mutations in colorectal cancer: a new biomarker?. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 176-177.	3.7	9
160	Neoadjuvant Strategies: Locally Advanced Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2017, 30, 383-386.	0.5	9
161	Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. <i>PLoS ONE</i> , 2018, 13, e0196245.	1.1	9
162	Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age. <i>JAMA Network Open</i> , 2020, 3, e2028644.	2.8	9

#	ARTICLE	IF	CITATIONS
163	Genomic analysis and selected molecular pathways in rare cancers. <i>Physical Biology</i> , 2012, 9, 065004.	0.8	8
164	The Current State of Targeted Agents in Rectal Cancer. <i>International Journal of Surgical Oncology</i> , 2012, 2012, 1-14.	0.3	8
165	Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. <i>Cancer Medicine</i> , 2021, 10, 4269-4281.	1.3	8
166	Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. <i>Carcinogenesis</i> , 2012, 33, 841-847.	1.3	7
167	Optimal management of squamous cell carcinoma of the anal canal: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 877-886.	1.1	7
168	Cetuximab in Refractory Squamous Cell Carcinoma of the Anal Canal. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 198-200.	0.6	7
169	Quality of life after intensity-modulated radiation therapy for anal cancer. <i>Journal of Radiation Oncology</i> , 2015, 4, 291-298.	0.7	7
170	Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 721-726.	0.6	7
171	Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. <i>Annals of Surgical Oncology</i> , 2017, 24, 3667-3672.	0.7	7
172	Metastatic Anal Cancer and Novel Agents. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 133-142.	0.6	7
173	A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. <i>Clinical Colorectal Cancer</i> , 2019, 18, 301-306.	1.0	7
174	Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer. <i>Journal of Experimental Pharmacology</i> , 2020, Volume 12, 475-485.	1.5	7
175	Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 901-908.	1.1	7
176	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1426-e1427.	1.9	7
177	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , 2021, 17, 607-614.	1.4	7
178	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. <i>Oncologist</i> , 2022, 27, 40-47.	1.9	7
179	Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. <i>Clinical Colorectal Cancer</i> , 2008, 7, 55-59.	1.0	6
180	Role of the MET-HGF axis in colorectal cancer: precepts and prospects. <i>Colorectal Cancer</i> , 2012, 1, 329-341.	0.8	6

#	ARTICLE	IF	CITATIONS
181	Optimal Treatment Strategies for Anal Cancer. <i>Current Treatment Options in Oncology</i> , 2014, 15, 443-455.	1.3	6
182	Pharmacotherapy of Anal Cancer. <i>Drugs</i> , 2017, 77, 1519-1530.	4.9	6
183	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	6
184	Early-Onset Colorectal Cancer: The Mystery Remains. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1608-1610.	3.0	6
185	K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 174-5.	0.3	6
186	Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 974-984.	0.4	5
187	Experimental and investigational drugs for the treatment of anal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 941-950.	1.9	4
188	Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. <i>Advances in Radiation Oncology</i> , 2018, 3, 595-600.	0.6	4
189	CEA as a blood-based biomarker in anal cancer. <i>Oncotarget</i> , 2021, 12, 1037-1045.	0.8	4
190	Colorectal cancer during pregnancy or postpartum: Case series and literature review. <i>Obstetric Medicine</i> , 0, , 1753495X2110412.	0.5	4
191	Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 169-172.	1.4	4
192	Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, 65-8.	0.8	4
193	Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, E82-5.	0.6	4
194	The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 968-961.	0.3	4
195	Colorectal Cancer Genomics by Genetic Ancestry. <i>Cancer Discovery</i> , 2022, 12, 1187-1188.	7.7	4
196	The Role of Immunotherapy in the Treatment of Anal Cancer and Future Strategies. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1073-1085.	1.3	4
197	Biological agents versus chemotherapy in the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 1251-1271.	0.9	3
198	Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009, 6, 16-17.	1.7	3

#	ARTICLE	IF	CITATIONS
199	Challenges of Efficacy Assessments in Pseudomyxoma Peritonea. <i>Oncologist</i> , 2015, 20, e3-4.	1.9	3
200	Circulating DNA biomarkers: a primer for metastatic colorectal cancer?. <i>Lancet Oncology</i> , The, 2015, 16, 878-879.	5.1	3
201	Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection. <i>Annals of Surgical Oncology</i> , 2017, 24, 2595-2595.	0.7	3
202	More questions regarding HIPEC in colorectal carcinomatosis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 744-745.	3.7	3
203	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 523-534.	0.9	3
204	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020, 19, 248-255.e6.	1.0	3
205	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. <i>Investigational New Drugs</i> , 2020, 38, 1763-1773.	1.2	3
206	Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, 661-661.	0.8	3
207	Combining Targeted Therapies to Enhance the Effectiveness of Chemotherapy in Patients with Treatment-Refractory Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2007, 6, S53-S59.	1.0	2
208	Commentary: Practice Patterns and Potential Impact on Quality Measures for a Practicing Physician. <i>Journal of Oncology Practice</i> , 2009, 5, 233-235.	2.5	2
209	Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: A case series. <i>Acta OncolÁgica</i> , 2013, 52, 1044-1046.	0.8	2
210	Multidisciplinary management of stage IV colon cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2016, 27, 213-218.	0.2	2
211	Pharmacotherapeutic considerations for elderly patients with colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 2139-2160.	0.9	2
212	Safety considerations with new treatment regimens for anal cancer. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 889-902.	1.0	2
213	Management of Refractory Metastatic Anal Squamous Cell Carcinoma Following Disease Progression on Traditional Chemoradiation Therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2012, 3, 161-9.	0.2	2
214	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. <i>Journal of the National Cancer Institute</i> , 2022, 114, 819-828.	3.0	2
215	Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2022, 13, 647-656.	0.6	2
216	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020, 16, 525-525.	1.4	1

#	ARTICLE	IF	CITATIONS
217	Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. Radiotherapy and Oncology, 2020, 151, 56-57.	0.3	1
218	Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. Clinical Colorectal Cancer, 2020, 19, e189-e199.	1.0	1
219	TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?. Lancet Oncology, The, 2020, 21, 326-327.	5.1	1
220	BRAF V600E mutated metastatic colorectal cancer: current progress and future directions. Expert Opinion on Biological Therapy, 2021, 21, 1311-1313.	1.4	1
221	Pancreatic Cancer in Young Adults: Can Innovative Approaches Lead to Better Outcomes?. Journal of the National Cancer Institute, 2021, 113, 1125-1126.	3.0	1
222	Abstract 101: Racial differences in somatic mutations among patients with early-onset colorectal cancer. , 2021, , .		1
223	Colorectal cancer adjuvant chemotherapy trends among a nonelderly veteran cohort at a southern veterans health administration. Cancer Reports, 2021, , e1508.	0.6	1
224	Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. Clinical Colorectal Cancer, 2021, 20, 368-371.	1.0	1
225	The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix.. Journal of Clinical Oncology, 2013, 31, 199-199.	0.8	1
226	Perspectives on Clinical Trials for Gastrointestinal Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 40-43.	1.8	1
227	Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report. Clinical Colorectal Cancer, 2022, , .	1.0	1
228	The treatment of colorectal carcinoma: standard chemotherapy and beyond. Clinical Advances in Hematology and Oncology, 2004, 2, 592-8.	0.3	1
229	Aggressive Combined Modality Therapy for Recurrent Colorectal Cancer Involving the Duodenum and Pancreas: A Report of 5 Cases. Clinical Colorectal Cancer, 2008, 7, 338-342.	1.0	0
230	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. Colorectal Cancer, 2012, 1, 15-16.	0.8	0
231	Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 233-242.	1.0	0
232	Will PICCOLO affect metastatic colorectal cancer therapy?. Lancet Oncology, The, 2013, 14, 679-680.	5.1	0
233	Colorectal Cancer Survivorship Management. , 2015, , 71-93.		0
234	Preface. Surgical Oncology Clinics of North America, 2017, 26, xv-xvi.	0.6	0

#	ARTICLE	IF	CITATIONS
235	In Reply. <i>Oncologist</i> , 2020, 25, e1252-e1253.	1.9	0
236	Immunotherapy for GI Cancers. <i>Advances in Oncology</i> , 2021, 1, 283-295.	0.1	0
237	Squamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis. <i>Clinical Colorectal Cancer</i> , 2021, 20, e210-e213.	1.0	0
238	A phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 450-450.	0.8	0
239	Rare development of bone metastases in appendiceal epithelial neoplasm: case report. <i>Research</i> , 0, 1, .	0.0	0
240	Managing Non-Hepatic Metastatic Sites: Lung and CNS. , 2019, , 495-508.		0
241	Squamous Cell Carcinoma of the Anal Canal. , 2019, , 175-184.		0
242	418â€¦A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors. , 2020, , .		0
243	Carcinoma of the anal canal: small steps in treatment advances. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 662-9.	0.3	0